Back to Search Results
Study Complete
Sponsor ID
20050102

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

Sponsor ID
20050102
Clinicaltrials.gov ID
NCT00135304
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.

Additional Study Details

Phase
Phase 4
Product
cinacalcet hcl
Type
Interventional
Masking
None (Open Label)
Enrollment
170
Additional Study Details

Protocol Summary

Primary Outcome Measures

Achieving the NKF-K/DOQI targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (less than 55 mg^2/dL^2) during the assessment phase

Timeframe: Weeks 17 - 27

Secondary Outcome Measures

Absolute Change from Baseline for P During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Proportion of Participants with ≥ 30% Reduction from Baseline in Mean iPTH During the Assessment Phase

Timeframe: Baseline and Weeks 17-27

Percent Change from Baseline for Calcium During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Percent Change from Baseline for Phosphorus During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Percent Change from Baseline for Ca x P During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Percent Change from Baseline for iPTH During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Proportion of Participants who Attained the K/DOQI Target Range for Ca x P During the Assessment Phase.

Timeframe: Weeks 17 - 27

Proportion of Participants who Attained the K/DOQI Target Range for Ca During the Assessment Phase

Timeframe: Weeks 17-27

Proportion of Participants who Attained the K/DOQI Target Range for iPTH During the Assessment Phase

Timeframe: Weeks 17-27

Proportion of Participants who Attained the K/DOQI Target Range for P During the Assessment Phase.

Timeframe: Weeks 17-27

Absolute Change from Baseline for iPTH During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Absolute Change from Baseline for Ca During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Absolute Change from Baseline for Ca x P During the Assessment Phase

Timeframe: Baseline to weeks 17-27

Study Documents

Study Synopsis
Available Language(s): English
Download Document(s)

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Hyperparathyroidism
    • Sex
    All
    Trial Dates
    Aug 2005 - Oct 2006
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - On hemodialysis for at least 3 months and have received intravenous vitamin D therapy (paricalcitol or doxercalciferol) for at least 3 months prior to entering screening - Historical iPTH 150-800 pg/ml (or biPTH 80-430 pg/ml) within 6 months and corrected serum Ca greater than 8.4 mg/dl within 2 months prior to screening period. For subjects with biPTH 80-160 pg/ml (iPTH 150-300 pg/ml), Ca x P must be greater than 55 mg²/dl² within 2 months prior to the screening period - Screening (pre-washout) biPTH 80-430 pg/ml and a corrected serum Ca level greater than 8.4 mg/dl. For subjects with biPTH 80-160 pg/ml Ca x P must be also greater than 55 mg²/dl² - Baseline mean biPTH (post-washout) greater than 160 pg/ml and mean corrected Ca greater than 8.4 mg/dl
    Exclusion Criteria:
    - Parathyroidectomy in the 3 month period prior to screening - Current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets - Use of investigational drug or device or participation in a trial of investigational drug or device within 30 days of screening - Females of child bearing potential who are pregnant (e.g., positive pregnancy test) or are breast feeding or who refuse to use highly effective contraceptive measures (as determined by the investigator) throughout the study - Previously participated in this or any other Sensipar® study or has received or is receiving Sensipar® as a commercially available product